It was in 1975 when scientists from Ayerst (now Pfizer) discovered a novel compound called rapamycin (also known as Sirolimus) in bacteria on Rapa Nui(Easter Island) in Chile. In 1999 rapamycin obtained FDA approval for the prevention of acute rejection of renal transplant. Unknown at the time, rapamycin would become the most potent anti-aging drug that humans currently hold.

This is the first article of a two-part series on rapamycin.

The profound effect rapamycin has on lifespan was first observed in yeast cells, and later confirmed in every model organism tested, including the nematode C. elegans, fruit flies, and mice.

To test the interaction between senolytic removal of senescent cells and cellular reprograming, we designed a model combining these two interventions in an inducible overexpression system in Drosophila. First, we used the four Yamanaka factor based OKSM approach as this had been previously shown to induce pluripotent stem cells in mice [7], humans [29 – 31] and non-mammalian vertebrate and invertebrate species [32]. To make a senolytic factor for Drosophila, we took advantage of the mouse sequence (FOXO4-DRI [22]) to design an orthologous peptide based on the Drosophila foxo (forkhead box, sub-group O) gene [33]. We then characterized effects of these two interventions independently as well as in combination.

We began by looking at the effect of OKSM and Sen on stem cells in an intestinal stem cell (ISC) model [34, 35]. We chose to investigate phenotypic effects specifically in the digestive system of Drosophila (Supplementary Figure 1). As in mammals, the Drosophila gastric lining has a high turnover of cells which is enabled by stem cell pools that replenish the epithelia [34]. Age-dependent loss of stem cells and degradation of barrier function has been shown to contribute to age-dependent functional decline and mortality in Drosophila [36]. The Drosophila gut is composed of four cell types: enterocytes (ECs or absorptive cells), enteroendocrine (EEs or secretory cells), enteroblasts (EBs or transit amplifying cells) and intestinal stem cells (ISCs).

Biotech company Mogling Bio has successfully has completed its first seed investment round with a sole investor, Kizoo Technology Capital.

Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.

Ageing causes stem cells to lose their normal structure by increased activity of the protein CDC42. Normalising CDC42 activity can restore structure, order and functionality in those aged stem cells.

Summary: Researchers have developed a new ophthalmological device that can detect degenerative visual problems such as age-related macular degeneration long before the onset of the first symptoms.

Source: EPFL

Researchers at an EPFL lab have developed an ophthalmological device that can be used to diagnose some degenerative eye disorders long before the onset of the first symptoms. In early clinical trials, the prototype was shown to produce images with a sufficient degree of precision in just five seconds.